{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T05:21:46Z","timestamp":1698729706852},"reference-count":7,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.leukres.2009.03.024","type":"journal-article","created":{"date-parts":[[2009,4,17]],"date-time":"2009-04-17T04:43:16Z","timestamp":1239943396000},"page":"e164-e165","source":"Crossref","is-referenced-by-count":6,"title":["CD8+ memory T cells predominate over na\u00efve T cells in therapy-free CML patients with sustained major molecular response"],"prefix":"10.1016","volume":"33","author":[{"given":"Kensuke","family":"Usuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokiko","family":"Nagamura-Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.03.024_bib1","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2009.03.024_bib2","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2009.03.024_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.leukres.2004.06.012","article-title":"CML cytogenetic relapse after cessation of imatinib therapy","volume":"29","author":"Usuki","year":"2005","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2009.03.024_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2009.03.024_bib5","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.03.024_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa","volume":"20","author":"Mahon","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.03.024_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/leu.2008.94","article-title":"Interferon-\u03b1 is able to maintain complete molecular remission induced by imatinib after its discontinuation","volume":"22","author":"Carella","year":"2008","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T07:50:07Z","timestamp":1545292207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":7,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0145212609001477"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.03.024","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}